Literature DB >> 31599958

Acute Lower Respiratory Infections Associated With Respiratory Syncytial Virus in Children With Underlying Congenital Heart Disease: Systematic Review and Meta-analysis.

Pa Saidou Chaw1, Stephanie Wen Lan Wong2, Steve Cunningham3, Harry Campbell2, Rafael Mikolajczyk1, Harish Nair2,4.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is the most common viral pathogen associated with acute lower respiratory infections (ALRIs), with significant childhood morbidity and mortality worldwide. Estimates reporting RSV-associated ALRI (RSV-ALRI) severity in children with congenital heart disease (CHD) are lacking, thus warranting the need to summarize the available data. We identified relevant studies to summarize the findings and conducted a meta-analysis of available data on RSV-associated ALRI hospitalizations in children aged <5 years, comparing those with underlying CHD to those without CHD.
METHODS: We conducted a systematic search of existing relevant literature and identified studies reporting hospitalization of children aged <5 years with RSV-ALRI with underlying or no CHD. We summarized the data and conducted (where possible) a random-effects meta-analysis to compare the 2 groups.
RESULTS: We included 18 studies that met our strict eligibility criteria. The risk of severe RSV-ALRI (odds ratio, 2.2; 95% confidence interval [CI], 1.6-2.8), the rate of hospitalization (incidence rate ratio, 2.8; 95% CI, 1.9-4.1), and the case-fatality ratio (risk ratio [RR], 16.5; 95% CI, 13.7-19.8) associated with RSV-ALRI was higher among children with underlying CHD as compared to those without no CHD. The risk of admission to the intensive care unit (RR, 3.9; 95% CI, 3.4-4.5), need for supplemental oxygen therapy (RR, 3.4; 95% CI, .5-21.1), and need for mechanical ventilation (RR, 4.1; 95% CI, 2.1-8.0) was also higher among children with underlying CHD.
CONCLUSION: This is the most detailed review to show more-severe RSV-ALRI among children aged <5 years with underlying CHD, especially hemodynamically significant underlying CHD, as compared those without CHD, supporting a need for improved RSV prophylactics and treatments that also have efficacy in children older than 1 year.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Respiratory syncytial virus; acute lower respiratory infections; congenital heart disease

Year:  2020        PMID: 31599958     DOI: 10.1093/infdis/jiz150

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

1.  Cyclophilin A Inhibits Human Respiratory Syncytial Virus (RSV) Replication by Binding to RSV-N through Its PPIase Activity.

Authors:  Wenzhang Liang; Yue Zhang; Miao Li; Fadhl Al-Shaebi; Jian Li; Jing Zhang; Lin Wei
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

2.  Systemic hypoxia inhibits T cell response by limiting mitobiogenesis via matrix substrate-level phosphorylation arrest.

Authors:  Amijai Saragovi; Ifat Abramovich; Ibrahim Omar; Eliran Arbib; Ori Toker; Eyal Gottlieb; Michael Berger
Journal:  Elife       Date:  2020-11-23       Impact factor: 8.140

3.  Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years (INSPIRE Study).

Authors:  Katrin Hartmann; Johannes G Liese; Daniel Kemmling; Christiane Prifert; Benedikt Weißbrich; Pushpike Thilakarathne; Joris Diels; Karin Weber; Andrea Streng
Journal:  J Infect Dis       Date:  2022-08-26       Impact factor: 7.759

4.  Association of Respiratory Syncytial Virus Infection and Underlying Risk Factors for Death Among Young Infants Who Died at University Teaching Hospital, Lusaka Zambia.

Authors:  Leah S Forman; William Macleod; Lawrence Mwananyanda; Geoffrey Kwenda; Rachel Pieciak; Zachariah Mupila; Caitriona Murphy; Donald Thea; Chilufya Chikoti; Baron Yankonde; Benard Ngoma; Charles Chimoga; Christopher J Gill
Journal:  Clin Infect Dis       Date:  2021-09-02       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.